Stocktoria
Xtant Medical Holdings, Inc. XTNT
NYSE American · XASE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2010-06-30
Xtant Medical Holdings, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.6M | $90.0M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M | $34.4M | $42.5M | $43.5M | $50.1M | $62.3M |
| R&D expense | $2.1M | $2.4M | $1.3M | $915,000 | $870,000 | $657,000 | $932,000 | $1.7M | $2.4M | $3.4M |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$3.9M | -$751,000 | -$2.3M | -$60.1M | -$37.8M | -$7.5M |
| Interest expense | $3.7M | $4.2M | $2.9M | $1.7M | $995,000 | $6.0M | $5.8M | $10.1M | $14.7M | $12.3M |
| Income tax | $2.0M | $187,000 | -$1.7M | $69,000 | — | $296,000 | $98,000 | — | $0 | $50,362 |
| Net income | $5.0M | -$16.4M | $660,000 | -$8.5M | -$4.8M | -$7.0M | -$8.2M | -$70.1M | -$52.4M | -$19.5M |
| EPS (diluted) | $0.03 | $-0.12 | $0.01 | $-0.09 | $-0.06 | $-0.25 | $-0.63 | $-5.97 | $-34.76 | $-18.46 |
| Operating cash flow | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439,000 | -$731,000 | -$413,000 | $1.2M | -$543,000 | -$14.4M |
| Free cash flow | $10.2M | -$16.0M | -$11.0M | -$7.1M | -$1.7M | -$2.3M | -$1.3M | $588,000 | — | — |
| Cash & equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M | $2.3M | $5.2M | $6.8M | $2.9M | $2.6M |
| Inventory | $30.3M | $38.6M | $36.9M | $17.3M | $17.9M | $21.4M | $16.1M | $17.3M | $22.4M | $26.3M |
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M | $41.5M | $43.2M | $46.4M | $105.7M | $144.1M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M | $27.0M | $87.4M | $90.2M | $164.4M | $151.2M |
| Shareholders' equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M | $14.5M | -$44.2M | -$43.8M | -$58.7M | -$7.1M |
Growth · year-over-year · Revenue CAGR 4.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +14.2% | +28.4% | +57.5% | +4.9% | +3.6% | -17.5% | -10.4% | -12.6% | -8.2% | +51.7% |
| Net income growth | — | -2592.3% | — | — | — | — | — | — | — | — |
| EPS growth | — | -1300.0% | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | -319.7% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001453593 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.